South Africa has yet to begin assessing GLP-1 obesity treatment for public sector patients, despite the World Health Organisation (WHO) recommending these medicines for long-term obesity management in December 2025. The Department of Health is considering adding GLP-1 medicines to its essential medicines list for diabetes treatment. However, it has not started evaluating their use specifically for obesity. Rebone Ntsie,…
Tag: Sun Pharma
-
GLP-1 Generics Could Reshape Local Obesity Market
A new wave of generic GLP-1 medicines could transform South Africa’s fast-growing obesity treatment market. Sun Pharma recently launched the country’s first generic semaglutide injection for type 2 diabetes through its Ranbaxy subsidiary. The South African Health Products Regulatory Authority (SAHPRA) is considering another 13 semaglutide applications. The opportunity is substantial. Morgan Stanley expects the global GLP-1 market to reach…
-
Sun Pharma’s Generic Semaglutide Gets SA Approval
Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell a generic semaglutide injection in South Africa. The South African Health Products Regulatory Authority, or SAHPRA, approved the medicine for adults with inadequately controlled type 2 diabetes. Semaglutide is the active ingredient in Novo Nordisk’s diabetes medicine Ozempic. It is also used in the company’s Wegovy weight-loss treatment. The…